Use of Machine Learning to Optimize Referral for Early Palliative Care: Are Prognostic Predictions Enough? In the article that accompanies this editorial, Camus et al 7 have updated and reanalyzed ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a complete response, reported Jun Zhu, MD, of ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

In Asia, PTCL diagnosis and management are hindered by the lack of available domain experts, limitations in infrastructure support and funding, and substantial challenges in accessing novel drugs; ...

The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life ...

T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific genetic ...

Kyowa Kirin Co ((KYKOF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...